• Explore /
  • Poster
  • / A phase I study to evaluate the safety of trigriluzole (BHV-4157) in combination with PD-1 blocking antibodies.

A phase I study to evaluate the safety of trigriluzole (BHV-4157) in combination with PD-1 blocking antibodies.

Abstract Poster

Authors

null

Ann W. Silk

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

Ann W. Silk, Robert Berman, Vlad Coric, Laura Ruggiero, Allen B. Reitz, Weichung Shih, Michael P. Kane, Janice M. Mehnert, Jeffrey C Pelletier, Andrew Zloza, James Steven Goydos

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A

Track

Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses

Sub Track

Metabolism

Clinical Trial Registration Number

NCT03229278

Citation

J Clin Oncol 36, 2018 (suppl 5S; abstr TPS80)

DOI

10.1200/JCO.2018.36.5_suppl.TPS80

Abstract #

TPS80

Poster Bd #

N1

Abstract Disclosures

Similar Posters

First Author: Zev A. Wainberg

First Author: Mehmet Akce

Poster

2020 ASCO-SITC Clinical Immuno-Oncology Symposium

A phase Ib study of troriluzole (BHV-4157) in combination with nivolumab.

A phase Ib study of troriluzole (BHV-4157) in combination with nivolumab.

First Author: Ann W. Silk

First Author: Mark R. Middleton